Why Israel is a benchmark medical-cannabis market

Israel pioneered medical cannabis. Raphael Mechoulam isolated THC and CBD in the 1960s at Hebrew University. Israeli clinicians have been prescribing cannabinoid medications for longer than most regulators in other countries have been writing rules about it. The result: a small but extraordinarily sophisticated market, with prescribing protocols, patient-monitoring practices, and supply-chain standards that influence regulatory thinking globally.

For a Thai exporter, the Israeli market is small in volume but disproportionately important in credibility. An exporter who can supply Israel under IMC supervision is, by that fact alone, supply-credible elsewhere. This piece walks through what IMC oversight actually requires.

The Israeli regulatory framework

The Israeli Medical Cannabis Agency (IMC) sits within the Ministry of Health and is the single point of authority for the entire medical-cannabis pathway. Imports, domestic cultivation, manufacture, distribution, and dispensing all flow through IMC oversight.

Three IMC standards matter for an importer:

IMC-GAP — Israeli Medical Cannabis Agency Good Agricultural Practice. Governs cultivation. For domestic Israeli cultivators, IMC-GAP is the operational standard. For imported origin material, IMC accepts equivalent national standards (TH-GACP for Thailand, EU-GACP for European origin, Health Canada's framework for Canada) on the strength of recognition agreements and case-by-case audit.

IMC-GMP — Israeli Medical Cannabis Agency Good Manufacturing Practice. Governs post-harvest manufacture (drying, curing, trim, packaging). IMC-GMP is a tighter standard than typical agricultural processing — closer to pharmaceutical GMP than to food-grade processing. Imported material must be processed under conditions IMC will accept as IMC-GMP equivalent, which in practice means EU-GMP certification or a credible IMC-recognised national equivalent.

Patient registry and prescription rules. IMC maintains a registry of prescribed patients, prescribers, and authorised products. Every prescription is tied to a specific approved product, a specific patient, and a specific indication.

What licensed Israeli importers verify before sourcing

The verification process is similar in structure to Australia and Germany but with Israel-specific emphases:

Cultivation foundation

TH-GACP certification (or origin-country equivalent)
Site licence and audit report
Pesticide regime documentation aligned to Israel's regulated MRL list
Water testing and inputs documentation

Post-harvest (the IMC-GMP focus)

EU-GMP certification, or written declaration of IMC-GMP equivalent processing with audit-ready evidence
Quality manual, master batch records, deviation procedures
Validation studies for processing equipment

Per-batch quality

ISO/IEC 17025-accredited CoA covering the full panel (cannabinoids, terpenes, microbial, residual solvents, pesticides, heavy metals, mycotoxins) — Israel reads CoAs carefully
Cultivar identity and stability — Israeli prescribers have been selecting cultivars by genetic line for decades, and supply contracts typically specify cultivar lock with a tolerance band
Retained samples held at the manufacturer for the labelled shelf life

Pharmacovigilance readiness

Adverse-event handling procedure with same-week response capability
Batch-level traceability through the dispensing pharmacy
Recall procedure documented and rehearsed

Chain-of-custody to dispensing

Cold-chain protocol with continuous logging
IMC-recognised import broker or distribution partner
Customs pre-clearance arrangements

What makes the Israeli prescriber distinct

Israeli prescribers — particularly those in pain medicine, oncology-supportive care, paediatric epilepsy, PTSD, and palliative care — tend to be more clinically detailed in their cultivar specifications than their counterparts in many other markets. Several reasons:

Longer institutional memory. Some Israeli prescribers have been writing cannabis prescriptions for 15-20 years. They have developed personal protocols around specific cultivars and specific cannabinoid:terpene combinations.

Patient-monitoring discipline. The IMC patient registry creates a culture where prescribers track outcomes per cultivar across their patient cohort. A cultivar that delivers inconsistent results gets dropped from prescribing rotations quickly.

Research culture. Many Israeli clinical centres run formal cannabis-medicine research programmes. The cultivar specifications in those protocols are exacting and the supply-chain expectations are equally so.

The practical implication for Thai exporters: an Israeli importer evaluating supply will scrutinise the cultivar identity claim, the genetic-stock provenance, and the cannabinoid + terpene profile stability across batches. Marketing language fails fast in this market.

What licensed Israeli importers will not accept

Equally clarifying is the list of what doesn't pass:

Cultivars without documented genetic stock and propagation records
CoAs that lack quantified terpene profiles or that report only "total terpenes"
Post-harvest manufacture without GMP-equivalent documentation, regardless of how clean the cultivation was
Cold-chain protocols without continuous logging, or with manual-only humidity verification
Strain swaps mid-contract without notification and re-test
Documentation pack that takes longer than ~5 business days to produce on first request

These aren't arbitrary preferences. They're the operational expression of a market that has been doing this longer than most.

Volume vs credibility — the trade

The Israeli medical-cannabis market is materially smaller than Germany's or Australia's. A Thai exporter may earn far less revenue from Israel than from those larger markets. But the credibility transfer is real:

An importer in Australia evaluating Thai supply will weigh "supplies licensed Israeli importers" as a substantial signal
Investors evaluating a Thai exporter will treat IMC-recognised supply as an indicator of quality discipline
Regulators in newer medical-cannabis markets often look at IMC-recognised exporters first when evaluating applications

We pursue Israeli supply not for volume but because the standard there is the standard everywhere else is moving toward.

Where the Israeli market is heading

Three trends to track:

Patient population is plateauing rather than growing rapidly. The Israeli regulatory environment hasn't loosened significantly in the past few years; patient growth tracks demographic and clinical-need expansion rather than regulatory expansion.

Cultivar consolidation. Prescribers and IMC are gravitating toward a smaller number of well-characterised cultivars. New cultivars are entering the market less frequently than they once did.

Export-oriented Israeli production. Israeli domestic cultivators are increasingly looking at export. This will reshape the inbound-supply landscape over the coming years; Thai exporters who establish trust in the Israeli market now will be better positioned as the competitive dynamics shift.

How CannaBless aligns to IMC expectations

We supply licensed Israeli importers because operating to IMC-recognised standards is the single best forcing-function we have for our quality discipline. Concretely:

TH-GACP cultivation with documentation aligned to IMC-GAP recognition pathways
Post-harvest manufacture under IMC-GMP-equivalent conditions
ISO/IEC 17025 CoA per batch with full cannabinoid + terpene profile and detailed contaminant testing
Cultivar identity locked through written supply contracts
Genetic stock documented and propagation records retained
Cold-chain protocol with continuous logging

If you're a licensed Israeli importer evaluating Thai supply, the documentation pack is the first request. The conversation that follows is one we welcome — Israeli scrutiny is the kind of pressure good supply chains improve under. Patients across Israel depend on that pressure being applied.